Abstract Aims We aimed to review the observational and randomised clinical trial evidence and provide pragmatic recommendations for using continuous glucose monitoring (CGM) in individuals living with noninsulin‐treated type 2 diabetes (T2DM). Materials and Methods We first undertook a narrative review of observational studies that enrolled noninsulin‐users or mixed populations of noninsulin and insulin‐users with T2DM as well as randomised controlled trials (RCTs) that enrolled mixed populations with T2DM. We then performed a systematic review of the RCTs that specifically enrolled noninsulin‐treated populations with T2DM and compared CGM to BGM/usual care. A meta‐analysis of glycaemic outcomes was conducted with predefined subgroups based on CGM type. Results RCTs in mixed populations and observational studies demonstrated a largely consistent benefit of CGM on glycaemic and nonglycaemic outcomes with cost effectiveness and reduced healthcare resource utilisation. The meta‐analysis of RCTs in noninsulin users included 8 studies encompassing 541 participants, among whom 297 (55%) were assigned to the CGM group. CGM was associated with significantly reduced HbA1c (weighted mean difference WMD −0.37%; 95% CI −0.49, −0.24; p < 0.00001; I 2 = 0%), increased % time in range (WMD 8.84; 95% CI 4.62, 13.06; p < 0.0001; I 2 = 0%) and lower % time above range (WMD −8.14; 95% CI −12.66, −3.63; p = 0.0004; I 2 = 0%). There were no significant subgroup differences. Conclusions CGM use in noninsulin‐treated individuals living with T2DM was associated with improved glycaemic outcomes and patient experience, reduced health care resource utilisation, and acceptable cost‐effectiveness. These findings provide additional evidence to support CGM use among people living with T2DM who are not using insulin therapy.
Aronson et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: